Incidence, treatment options, and outcomes of lung cancer in patients with chronic obstructive pulmonary disease

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 2, 2012, Pages 131-137

  Schroedl, Clara ^a   Kalhan, Ravi ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

chronic obstructive pulmonary disease; incidence; lung cancer; treatment

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID;

AIRWAY OBSTRUCTION; CANCER RISK; CANCER STAGING; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; EARLY CANCER; HUMAN; INFLAMMATION; LOBECTOMY; LUNG CANCER; RADIOFREQUENCY ABLATION; REVIEW; SAFETY; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CATHETER ABLATION; FEMALE; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; PNEUMONECTOMY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOSURGERY; SMOKING; TREATMENT OUTCOME; UNITED STATES;

EID: 84856678193     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834f2080     Document Type: Review

References (77)

1. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD. Version 1.2. New York: American Thoracic Society; 2004. http://www.thoracic.org/go/copd. [Accessed 8 September 2005]
2. Miniño AM. Death in the United States, 2009. NCHS data brief, no 64. Hyattsville, MD: National Center for Health Statistics; 2011.
3. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2007 incidence and mortality web-based report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute 2010. www.cdc.gov/uscs.
4. Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences: clinical impact, mechanisms, and potential for early intervention. COPD 2008; 5:235-256.
5. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009; 34:380-386.
6. Caplin M, Festenstein F. Relation between lung cancer, chronic bronchitis, and airways obstruction. Br Med J 1975; 3:678-680.
7. Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One 2011; 6:e17479.
8. Kiri VA, Soriano J, Visick G, Fabbri L. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J 2010; 19:57-61.
9. De Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with COPD: Incidence and predicting factors. Am J Respir Crit Care Med 2011; 184:913-919.
10. Smith BD, Smith GL, Hurria A, et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27:2758-2765.
11. McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62:411-415. (Pubitemid 46698390)
12. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:948-955.
13. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163:1475-1480. (Pubitemid 36758921)
14. Tockman MS, Anthonisen NR, Wright EC, Donithan MG. Airways obstruction and the risk for lung cancer. Ann Intern Med 1987; 106:512-518. (Pubitemid 17095034)
15. Broderick P, Wang Y, Vijayakrishnan J, et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res 2009; 69:6633-6641.
16. Wan ES, Silverman EK. Genetics of COPD and emphysema. Chest 2009; 136:859-866.
17. Sundar IK, Mullapudi N, Yao H, et al. Lung cancer and its association with & chronic obstructive pulmonary disease: update on nexus of epigenetics. Curr Opin Pulm Med 2011; 17:279-285.
18. Qu P, Roberts J, Li Y, et al. Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. Lung Cancer 2009; 63:341-347.
19. Tauler J, Mulshine JL. Lung cancer and inflammation: interaction of chemo-kines and hnRNPs. Curr Opin Pharmacol 2009; 9:384-388.
20. Qu P, Du H, Wang X, Yan C. Matrix metalloproteinase 12 overexpression in lung epithelial cells plays a key role in emphysema to lung bronchioalveolar adenocarcinoma transition. Cancer Res 2009; 69:7252-7261.
21. Goldkorn T, Filosto S. Lung injury and cancer: mechanistic insights into ceramide and EGFR signaling under cigarette smoke. Am J Respir Cell Mol Biol 2010; 43:259-268.
22. Herr C, Greulich T, Koczulla RA, et al. The role of vitamin D in pulmonary disease: COPD, asthma, infection, and cancer. Respir Res 2011; 12:31.
23. Adcock IM, Caramori G, Barnes PJ. Chronic obstructive pulmonary disease and lung cancer: new molecular insights. Respiration 2011; 81:265-284.
24. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990; 323:1228-1233. (Pubitemid 20366527)
25. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-1437. (Pubitemid 23143844)
26. Provenzale D, Schmitt C, Wong JB. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol 1999; 94:2043-2053. (Pubitemid 29374530)
27. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31:1334-1356.
28. Malkinson AM. Role of inflammation in mouse lung tumorigenesis: a review. Exp Lung Res 2005; 31:57-82. (Pubitemid 40053570)
29. Miller YE, Keith RL. Inhaled corticosteroids and lung cancer chemoprevention. Am J Respir Crit Care Med 2007; 175:636-637. (Pubitemid 46536476)
30. Parimon T, Chien JW, Bryson CL, et al. Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:712-719. (Pubitemid 46536487)
31. Veronesi G, Szabo E, Decensi A, et al. Randomized phase II trial of inhaled & budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) 2011; 4:34-42.
32. Castaldi PJ, Cho MH, Cohn M, et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet 2010; 19:526-534.
33. Smolonska J, Wijmenga C, Postma DS, Boezen HM. Meta-analyses on suspected chronic obstructive pulmonary disease genes: a summary of 20 years' research. Am J Respir Critical Care Med 2009; 180:618-631.
34. Carlsten C, Sagoo GS, Frodsham AJ, et al. Glutathione S-transferase M1 (GSTM1) polymorphisms and lung cancer: a literature-based systematic HuGE review and meta-analysis. Am J Epidemiol 2008; 167:759-774. (Pubitemid 351451750)
35. Hung RJ, Christiani DC, Risch A, et al. International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev 2008; 17:3081-3089.
36. Hung RJ, McKay JD, Gaborieau V, et al. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008; 452:633-637. (Pubitemid 351483367)
37. Thorgeirsson TE, Geller F, Sulem P, et al. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008; 452:638-642. (Pubitemid 351483366)
38. Amos CI, Wu X, Broderick P, et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008; 40:616-622. (Pubitemid 351601203)
39. Lambrechts D, Buysschaert I, Zanen P, et al. The 15q24/25 susceptibility & variant for lung cancer and chronic obstructive pulmonary disease is asso ciated with emphysema. Am J Respir Crit Care Med 2010; 181:486-493.
40. Wang J, Spitz MR, Amos CI, et al. Mediating effects of smoking and chronic & obstructive pulmonary disease on the relation between the CHRNA5-A3 genetic locus and lung cancer risk. Cancer 2010; 116:3458-3462.
41. Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med 2008; 168:1097-1103. (Pubitemid 351749227)
42. Wisnivesky JP, Bonomi M, Henschke C, et al. Radiation therapy for the treatment of unresected stage I-II nonsmall cell lung cancer. Chest 2005; 128:1461-1467. (Pubitemid 41324433)
43. Colice GL, Shafazand S, Griffin JP, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:161S-177S. (Pubitemid 47502806)
44. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radio-therapy). Eur Respir J 2009; 34:17-41.
45. Cai XW, Xu LY, Wang L, et al. Comparative survival in patients with post-& resection recurrent versus newly diagnosed nonsmall-cell lung cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys 2010; 76:1100-1105.
46. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database study. Ann Thorac Surg 2009; 88:362-370; discussion 370-371.
47. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 nonsmall cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995; 60:615-622; discussion 622-623.
48. Nakamura H, Kazuyuki S, Kawasaki N, et al. History of limited resection for nonsmall cell lung cancer. Ann Thorac Cardiovasc Surg 2005; 11:356-362.
49. Bilfinger TV, Baram D. Sublobar resection in nonsmall cell lung carcinoma. Curr Opin Pulm Med 2008; 14:292-296. (Pubitemid 351786539)
50. El-Sherif A, Fernando HC, Santos R, et al. Margin and local recurrence after sublobar resection of nonsmall cell lung cancer. Ann Surg Oncol 2007; 14:2400-2405. (Pubitemid 47174921)
51. Schuchert MJ, Pettiford BL, Keeley S, et al. Anatomic segmentectomy in the treatment of stage I nonsmall cell lung cancer. Ann Thorac Surg 2007; 84:926-932; discussion 932-933.
52. Okada M, Koike T, Higashiyama M, et al. Radical sublobar resection for small-sized nonsmall cell lung cancer: a multicenter study. J Thorac Cardiovasc Surg 2006; 132:769-775. (Pubitemid 44415874)
53. Sawabata N, Ohta M, Matsumura A, et al. Optimal distance of malignant negative margin in excision of nonsmall cell lung cancer: a multicenter prospective study. Ann Thorac Surg 2004; 77:415-420. (Pubitemid 38186481)
54. Santos R, Colonias A, Parda D, et al. Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with stage I nonsmall-cell lung cancer. Surgery 2003; 134:691-697; discussion 697. (Pubitemid 37411977)
55. D'Amato TA, Galloway M, Szydlowski G, et al. Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer. Chest 1998; 114:1112-1115. (Pubitemid 28495910)
56. Park BJ. Is surgical morbidity decreased with minimally invasive lobectomy? Cancer J 2011; 17:18-22.
57. Shennib H, Bogart J, Herndon JE, et al. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multiinstitutional cooperative group study. J Thorac Cardiovasc Surg 2005; 129:813-818. (Pubitemid 40487882)
58. McKenna RJ Jr, Fischel RJ, Brenner M, Gelb AF. Combined operations for lung volume reduction surgery and lung cancer. Chest 1996; 110:885-888. (Pubitemid 26347598)
59. Pompeo E, De Dominicis E, Ambrogi V, et al. Quality of life after tailored combined surgery for stage I nonsmall-cell lung cancer and severe emphysema. Ann Thorac Surg 2003; 76:1821-1827. (Pubitemid 37510484)
60. Choong CK, Meyers BF, Battafarano RJ, et al. Lung cancer resection combined with lung volume reduction in patients with severe emphysema. J Thorac Cardiovasc Surg 2004; 127:1323-1331. (Pubitemid 38560594)
61. Yacoub WN, Meyers BF. Surgical resection in combination with lung volume & reduction surgery for stage I nonsmall cell lung cancer. Semin Thorac Cardiovasc Surg 2010; 22:38-43.
62. Sekine Y, Iwata T, Chiyo M, et al. Minimal alteration of pulmonary function after lobectomy in lung cancer patients with chronic obstructive pulmonary disease. Ann Thorac Surg 2003; 76:356-361; discussion 362. (Pubitemid 36960568)
63. Leksell L. The stereotaxic method and radiosurgery of the brain. Acta Chir Scand 1951; 102:316-319.
64. McGarry RC, Papiez L, Williams M, et al. Stereotactic body radiation therapy of early-stage nonsmall-cell lung carcinoma: phase I study. Int J Radiat Oncol Biol Phys 2005; 63:1010-1015. (Pubitemid 41505277)
65. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage nonsmall-cell lung carcinoma: four-year results of a prospective phase II study. Int J Radiat Oncol Biol Phys 2009; 75:677-682.
66. Palma D, Lagerwaard F, Rodrigues G, et al. Curative treatment of stage I & nonsmall-cell lung cancer in patients with severe COPD: stereotactic radio therapy outcomes and systematic review. Int J Radiat Oncol Biol Phys 2011. doi:10.1016/j.ijrobp.2011.03.005. [Epub ahead of print]
67. Kimura T, Matsuura K, Murakami Y, et al. CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers? Int J Radiat Oncol Biol Phys 2006; 66:483-491. (Pubitemid 44332732)
68. Takeda A, Kunieda E, Ohashi T, et al. Severe COPD is correlated with mild radiation pneumonitis following stereotactic body radiotherapy. Chest 2011. doi:10.1378/chest.11-1193. [Epub ahead of print]
69. Hiraki T, Gobara H, Mimura H, et al. Percutaneous radiofrequency ablation of lung cancer. Lancet Oncol 2008; 9:604-605. (Pubitemid 351878046)
70. Healey TT, Dupuy DE. Radiofrequency ablation: a safe and effective treatment & in nonoperative patients with early-stage lung cancer. Cancer J 2011; 17:33
71. Pennathur A, Abbas G, Gooding WE, et al. Image-guided radiofrequency ablation of lung neoplasm in 100 consecutive patients by a thoracic surgical service. Ann Thorac Surg 2009; 88:1601-1606; discussion 1607-1608.
72. Beland MD, Wasser EJ, Mayo-Smith WW, Dupuy DE. Primary nonsmall cell & lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. Radiology 2010; 254:301-307.
73. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008; 9:621-628.
74. Huang L, Han Y, Zhao J, et al. Is radiofrequency thermal ablation a safe and & effective procedure in the treatment of pulmonary malignancies? Eur J Cardiothorac Surg 2011; 39:348-351.
75. Chua TC, Sarkar A, Saxena A, et al. Long-term outcome of image-guided percutaneous radiofrequency ablation of lung metastases: an open-labeled prospective trial of 148 patients. Ann Oncol 2010; 21:2017-2022.
76. Choe YH, Kim SR, Lee KS, et al. The use of PTC and RFA as treatment alternatives with low procedural morbidity in nonsmall cell lung cancer. Eur J Cancer 2009; 45:1773-1779.
77. Hess A, Palussiere J, Goyers JF, et al. Pulmonary radiofrequency ablation & in patients with a single lung: feasibility, efficacy, and tolerance. Radiology 2011; 258:635-642.